#	Pagina
attuale pagina	/open-h2020/projects/223864/index.html

Opendata, web and dolomites

TRIC-TB SIGNED

Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments.

Total Cost €

EC-Contrib. €

Partnership

Views

TRIC-TB project word cloud

Explore the words cloud of the TRIC-TB project. It provides you a very rough idea of what is the project "TRIC-TB" about.

mechanism 2016 benefit million world synergistic medicines ultimately significantly safety dosing bvl ethionamide compounds infection xdr regimen mtb mycobacterium lille percent 2nd university 9 glaxosmithkline infectious acting proprietary boost list human ind disease vital rates clinically cure bioversys mortality combinations multidrug leads 480 restore collaborators proven extensive people previously action resistant tuberculosis kill lower independently class sensitive patient placement overcoming treatment doses therapeutic drug optimization time killed starting scientific suffers strains therapy active 70 boosted pd exploration gsk038 gsk098 levels modulators communities extensively universal transcriptional line relapse reported once outcomes vivo resistance eth clinical compound status tb vitro mdr pk again first

Project "TRIC-TB" data sheet

The following table provides information about the project.

Coordinator	BIOVERSYS AG Organization address address: HOCHBERGERSTRASSE 60 C TECHNOLOGIEPARK BASEL city: BASEL postcode: 4057 website: www.bioversys.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Switzerland [CH]
Total cost	8˙373˙250 €
EC max contribution	6˙926˙375 € (83%)
Programme	1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
Code Call	H2020-JTI-IMI2-2018-16-single-stage
Funding Scheme	IMI2-RIA
Starting year	2019
Duration (year-month-day)	from 2019-05-01 to 2023-04-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	BIOVERSYS AG BIOVERSYS AG Organization address address: HOCHBERGERSTRASSE 60 C TECHNOLOGIEPARK BASEL city: BASEL postcode: 4057 website: www.bioversys.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (BASEL)	coordinator	6˙926˙375.00
2	GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL Organization address address: C/ SEVERO OCHOA NUMERO 2 PARQUE TECNOLOGICO DE MADRID city: TRES CANTOS postcode: 28760 website: www.gsk.es/html/investigacion/espana.html contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (TRES CANTOS)	participant	0.00

Map

Project objective

Tuberculosis (TB) is the world’s leading infectious disease. It killed 1.7 million people in 2016 and 10.4 million people developed active TB in the same year. In 2016, 480’000 of TB cases were multidrug-resistant (MDR-TB) and 9% percent of those cases are extensively drug-resistant (XDR), with mortality rates as high as 70%. Ethionamide (ETH) is a vital part of the WHO essential medicines list of 2nd-line TB therapy for MDR-TB, however, ETH suffers from significant levels of resistance and side effects at current dosing levels. BVL-GSK038 and BVL-GSK098 are proprietary to BioVersys/GlaxoSmithKline and have been developed through an extensive Lead Optimization program with collaborators from Lille University. Low doses of both compounds fully restore and “boost” the activity of ETH to rapidly kill Mycobacterium tuberculosis (Mtb) including MDR strains at significantly lower doses of ETH than previously reported, thus making MDR-TB sensitive to ETH once again. Through a comprehensive IND enabling package including in vitro and in vivo assessment of ETH with BVL-GSK038 and BVL-GSK098, including PK/PD, resistance development, safety, mechanism of action and synergistic studies with different drug compound combinations and then first in human clinical studies the consortium aims to:

i) Define the future placement of a boosted ETH (ETH BVL-GSK038 or BVL-GSK098) in a universal TB treatment regimen, including overcoming MDR-TB with improved safety, time to cure and relapse rates;

Ultimately, we expect to identify a new and clinically proven TB regimen that leads to better patient outcomes independently of the starting resistance status of the TB infection. The TB and wider scientific communities will benefit from an improved understanding of ETH and the exploration of a novel class of therapeutic compounds acting on transcriptional modulators (BVL-GSK038 and BVL-GSK098).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRIC-TB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TRIC-TB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

RespiriTB (2019)

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors